Amundi Supernus Pharmaceuticals, Inc. Transaction History
Amundi
- $276 Billion
- Q2 2025
A detailed history of Amundi transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Amundi holds 9,149 shares of SUPN stock, worth $438,786. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,149Holding current value
$438,786% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SUPN
# of Institutions
312Shares Held
61.7MCall Options Held
18.4KPut Options Held
0-
Black Rock Inc. New York, NY10.4MShares$498 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.21MShares$298 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.81MShares$231 Million2.66% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$145 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.76MShares$132 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.57B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...